Grifols, S.A.

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q4 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BARCELONA, Spain, and SAN CARLOS, Calif., Sept. 7, 2020 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced it has entered into a transaction.

Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome

ADMA Biologics

Cerus

Kamada

Liminal BioSciences

Sonnet BioTherapeutics

ThermoGenesis Holdings, Inc

T2 Biosystems

Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use of investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients.

These Plasma Stocks Are Surging After FDA's Convalescent EUA

Takeda Pharmaceutical

The results provide more justification for the FDA to grant the substance emergency use authorization.

Convalescent Plasma Found to Reduce COVID-19 Death Rate in New Study

BARCELONA, July 28, 2020 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing people's health and well-being, today announced it has.

Grifols delivers first manufactured batches of its anti-SARS-CoV-2 hyperimmune globulin for clinical trials

- Grifols makes a significant investment to become the only large-scale commercial manufacturer of plasma products in Canada, with a fractionation capacity of 1.5 million liters/year - The operation aligns with Grifols' commitment to helping countries reach self-sufficiency of.

Grifols to acquire Green Cross plasma fractionation facility in Montreal and a plasma collection organization in the U.S. for US$460 million

Novartis

Each company has a triad of COVID-19 projects, but they aren't in direct competition.

Better Coronavirus Stock: Grifols or Novartis?

Emergent BioSolutions

Antibodies of recovered patients can help treat people who are infected with the novel coronavirus.

Who Can Donate Plasma for COVID-19 Patients?

Johnson & Johnson

Merck

Dr. Reddy's Labs

Repligen

Zoetis

Much of the conversation about pharmaceutical stocks rests on the coronavirus, but these high-growth names have potential beyond the pandemic.

7 Pharmaceutical Stocks to Buy for Post-Pandemic Gains

AbbVie

Allergan

Bristol-Myers

Jazz Pharmaceuticals

Novo Nordisk

Sanofi

Pharmaceutical stocks dipped by a double-digit percentage in the first four months of 2020, trailing their biotech brethren. Still, there are standout companies in the industry group.

Why These 8 Pharma Stocks Are Outplaying 90% Of The Stock Market

GRFS vs. ZTS: Which Stock Is the Better Value Option?

GRFS vs. ZTS: Which Stock Should Value Investors Buy Now?

Grifols (GRFS) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.

How Grifols (GRFS) Stock Stands Out in a Strong Industry

Grifols (NASDAQ: GRFS) shares are trading higher on Thursday. The company announced it's working with the U.S.

Why Grifols Is Trading Higher Today

Grifols (GRFS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Grifols (GRFS) Upgraded to Strong Buy: Here's What You Should Know

Ionis Pharma

GRFS vs. IONS: Which Stock Is the Better Value Option?

GRFS or IONS: Which Is the Better Value Stock Right Now?

Shares of Grifols popped in massive volume Friday after the Spain-based pharmaceutical company gained Food and Drug Administration approval for an immunodeficiency treatment.

This Pharma Stock Dodged A Broad Slide For Drugmakers — Here's Why

GRFS vs. ORINY: Which Stock Is the Better Value Option?

GRFS or ORINY: Which Is the Better Value Stock Right Now?

News for Grifols, S.A. Stock (GRFS)